Immucell opened higher at $10.21, compared with its previous close of $10.19. In the last trading session, the stock traded between $10.21 and $10.33. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Immucell is now worth
$ 110.97
Giving a profit of
$ 10.97 (10.97%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.03 (+0.29%)
Day High
$10.33
Day Low
$10.21
Day Open
$10.21
Prev Close
$10.19
Volume
17,647
1W Return
0.69%
1M Return
4.71%
3M Return
-6.83%
6M Return
20.95%
1Y Return
63.00%
Fundamentals
Market Cap ($ Mn)
93
PE Ratio
142.86
PB Ratio
2.89
PEG Ratio
0.81
ROE
-3.63%
ROCE
-1.82%
EPS (TTM)
$0.20
Investment Returns
1 Week
0.69%
1 Month
4.71%
3 Months
-6.83%
6 Months
20.95%
9 Months
57.47%
Financials
Quarterly
All values in $ Mn
8.1
Mar 25
6.4
Jun 25
5.5
Sep 25
7.6
Dec 25
10.4
Mar 26
7.2
Jun 26
Updates
7Nov
ImmuCell to report Q1FY27 results on November 12 after market close
ImmuCell Corporation will announce unaudited Q1FY27 results on November 12, 2026. Conference call scheduled for November 13, 2026, at 9:00 am ET. Company expects no change to preliminary sales disclosed on October 12, 2026. Form 10-Q filing will occur after market close on November 12.
6 days ago
14Aug
ImmuCell Q2 revenue rises 11.5% to $7.2 million; net income up on settlement
ImmuCell Corporation reported Q2 2026 product sales of $7.2 million, up 11.5% YoY, driven by strong domestic growth of 27.7% which offset a 38.9% decline in international sales. Net income surged to $1.8 million, heavily influenced by a $2 million legal settlement. Gross margins contracted to 33.9% due to lower manufacturing volumes and cost shifts from the discontinued Re-Tain program. The company announced an $8 million two-phase capacity expansion to triple manufacturing capability, funded by cash on hand. Market share for First Defense increased to 19% in the U.S.
3mo ago
10Jul
ImmuCell Q2 sales rise 11.5% to $7.2 million
ImmuCell Corporation reported preliminary unaudited sales results for the second quarter of 2026, with total sales rising to $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025. The growth was primarily driven by a 27.7% increase in domestic sales, which offset a 38.9% decline in international sales during the period. For the six months ended June 30, 2026, total sales reached $17.5 million, a 20.9% increase compared to the same period in 2025.
